Fei Xu

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Ying Cheng, Wei Shi, Yunpeng Liu, 2022, The Lancet. Oncology.

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

Xiaojing Wang, X. Yao, Binqing Fu, 2021, Frontiers of Medicine.

An effective approach for treating unresectable hepatoblastoma in infants and children: Pre-operative transcatheter arterial chemoembolization

Jing Zhang, Shao-yi Zhou, Fei Xu, 2013, Oncology letters.

Clinical features related to hospital expenses for non-cystic fibrosis bronchiectasis in China

Feng Tian, Yan Zhang, Ying-qun Ji, 2020, The Journal of international medical research.

Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease

Jianying Zhou, Ning Li, Pei Zhang, 2022, BMC Pulmonary Medicine.

Clinical Characteristics of Pneumocystis Pneumonia After Parental Renal Transplantation

Xiaoling Xu, Tiantian Li, Fei Xu, 2020, Infection and drug resistance.

Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)

Chengzhi Zhou, Jian-zhen Shan, Jianhua Chen, 2023, Cancer Immunology, Immunotherapy.